Rhon-klinikum Ag · XETR:RHK
Rhon-klinikum — Q1 2015 Earnings Presentation
13 slides from Rhon-klinikum's earnings presentation, May 7, 2015
Slide 1: RHÖN-KLINIKUM AG First Quarter 2015 Results
RHÖN-KLINIKUM AG First Quarter 2015 Results May 07, 2015 Jens-Peter Neumann, CFO
Slide 2: Highlights of First Quarter 2015
Highlights of First Quarter 2015 Returning to normal Shareholder Structure as of 31 March 2015, Operational development on track with attractive underlying according to the most recent notifications of voting rights at that time volume growth of +10.4% to 191,730 inpatient and outpatient cases in Q1
Slide 3: P&L Key Figures Q1 2015
P&L Key Figures Q1 2015 Performance* Q1 2015 in € millions Operating P&L almost at normal level ... Organic revenue growth slightly squeezed by 2015 pricing Revenue 276 100.0% pressure in state of Hesse and deferred system surcharge Personnel expenses -175 63.4% for university clinics Increased mate
Slide 4: Special Management Focus in 2015
Special Management Focus in 2015 UKGM: operating performance stabilized in Q1 despite regulatory setbacks in 2015 Revenue growth +2,4% yoy EBITDA margin 5.5% Rebuilding of Bad Neustadt Campus kicked-of Reconstruction and capacity enlargement from 1,440 to >1,690 beds Optional integration of last rem
Slide 5: Q1 2015 Core Balance Sheet Figures
Q1 2015 Core Balance Sheet Figures € 1,817m € 1,817m € 870m 47.9% Non-current assets € 30m cash € 1,282m Equity ratio Equity 70.5% 52.1% € 947m Current assets € 35m Non-current liabilities 2.0% € 153m financial debt € 704m cash € 500m 27.5% Current liabilities Assets Equity & Liabilities After the s
Slide 6: Dividend Proposal 2015
Dividend Proposal 2015 The Management Board and Supervisory Board propose to the Annual General Meeting on 10 June 2015 the distribution of a dividend of € 0.80 per share (total dividend sum of € 58.8m) “Comprehensive participation by shareholders in the company’s success through payout ratios well
Slide 7: Potential Share Repurchase 2015
Potential Share Repurchase 2015 Framework for another share repurchase offer in the second half of 2015 The 2014 AGM authorised the Management Board to repurchase up to 10% of the registered share capital until 31 December 2015 No need for a new resolution at the 2015 AGM The 2014 share repurchase w
Slide 8: Further AGM Topics
Further AGM Topics Election of the Supervisory Board List of candidates with 8 shareholder representatives published Unanimous resolution of supervisory board reflects main criteria: general aptitude, qualification, independence, potential conflict of interest and future mandatory 30% proportion of
Slide 9: Guidance
Outlook FY 2015 Organic revenue growth +3-4% (main output prices ~ +1.6%; volumes +1-2%) KEY LEVERS Input prices: wages +2.8-3.2%; material costs +1.5-2% Positive and negative one-time effects in low double digit million amount area Excluding M&A activities GUIDANCE Group revenues € 1,080m to 1,120m
Slide 10: Financial Calendar
Financial Calendar FY 2015 June 10, 2015 Annual General Meeting (Jahrhunderthalle Frankfurt) August 6, 2015 Publication of the half year financial report as of June 30, 2015 November 6, 2015 Publication of interim report for the quarter ending Sept 30, 2015 All dates could be subject to modification
Slide 11: Appendix: Price Regulation 2015
Appendix: Price Regulation 2015 Average base rate increase in states with RHÖN hospitals Federal Total hospital system budget (weighted by RHÖN case mix) Level Reference number: +2.53% (wage sum increase) RHÖN effective base rate Benchmark (wage sum) Layer 1 Sector-specific cost index was at +1.44%
Slide 12: Appendix: Breakdown of Main Extraordinary Effects on FY 2015 EBITDA Outlook
Appendix: Breakdown of Main Extraordinary Effects on FY 2015 EBITDA Outlook 145m to 2015 will still be influenced by compensatory one-off items 155m A +20m successful abatement of legal action with social insurance carriers from 2011 B -10m deferred system surcharge for university clinics based on h
Slide 13: Disclaimer
Disclaimer • This document has been prepared by RHÖN-KLINIKUM AG (“RHÖN-KLINIKUM” or “the Company”) for information purposes only, solely for use at this presentation. It must be treated confidentially by attendees at such presentation and must not be distributed, passed on or otherwise disclosed. •